OBJECTIVE: Sorafenib, an oral multikinase inhibitor, prolonged progression-free survival when compared with placebo, as second-line therapy for patients with metastatic renal carcinoma (MRC). Grade 3/4 adverse events were reported in 12% of patients. This study presents sorafenib's efficacy and safety in a less selected cohort of patients enrolled in an expanded access program. METHODS: Patients with MRC received sorafenib 400 mg twice daily until disease progression. Tumor response was evaluated by RECIST criteria. Adverse events were graded by NCI common toxicity criteria. RESULTS: From November 2005 to August 2006, 58 patients were enrolled. The median progression-free survival was 7.5 months (95% CI: 5.4-11.3), and the best responses among 54 patients were 11 (20%) confirmed partial responses, 15 (28%) stable diseases for > or =6 months; 10 patients (18%) had early progression at 8 weeks. Grade 3/4 adverse events occurred in 37 patients (64%; 95% CI: 50%-76%), the most frequent being skin rash in 17 patients (29%), and hand-foot syndrome in 9 patients (15%). Thirty-six (62%) patients required dose reductions and/or treatment interruptions. CONCLUSIONS: Sorafenib is effective in a less selected patient population with MRC but leads to more toxicity than described previously.
OBJECTIVE:Sorafenib, an oral multikinase inhibitor, prolonged progression-free survival when compared with placebo, as second-line therapy for patients with metastatic renal carcinoma (MRC). Grade 3/4 adverse events were reported in 12% of patients. This study presents sorafenib's efficacy and safety in a less selected cohort of patients enrolled in an expanded access program. METHODS:Patients with MRC received sorafenib 400 mg twice daily until disease progression. Tumor response was evaluated by RECIST criteria. Adverse events were graded by NCI common toxicity criteria. RESULTS: From November 2005 to August 2006, 58 patients were enrolled. The median progression-free survival was 7.5 months (95% CI: 5.4-11.3), and the best responses among 54 patients were 11 (20%) confirmed partial responses, 15 (28%) stable diseases for > or =6 months; 10 patients (18%) had early progression at 8 weeks. Grade 3/4 adverse events occurred in 37 patients (64%; 95% CI: 50%-76%), the most frequent being skin rash in 17 patients (29%), and hand-foot syndrome in 9 patients (15%). Thirty-six (62%) patients required dose reductions and/or treatment interruptions. CONCLUSIONS:Sorafenib is effective in a less selected patient population with MRC but leads to more toxicity than described previously.
Authors: Shivanni Kummar; Helen X Chen; John Wright; Susan Holbeck; Myrtle Davis Millin; Joseph Tomaszewski; James Zweibel; Jerry Collins; James H Doroshow Journal: Nat Rev Drug Discov Date: 2010-10-29 Impact factor: 84.694
Authors: Thomas J Semrad; Courtney Eddings; Chong-Xian Pan; Derick H Lau; David Gandara; Laurel Beckett; Primo N Lara Journal: Invest New Drugs Date: 2011-10-21 Impact factor: 3.850
Authors: Hui-Ming Chang; Tochukwu M Okwuosa; Tiziano Scarabelli; Rohit Moudgil; Edward T H Yeh Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: Rana R McKay; Xun Lin; Julia J Perkins; Daniel Y C Heng; Ronit Simantov; Toni K Choueiri Journal: Eur Urol Date: 2014-02-26 Impact factor: 20.096
Authors: Yanning Liu; Guohua Lou; John T Norton; Chen Wang; Irawati Kandela; Shuai Tang; Nathaniel I Shank; Pankaj Gupta; Min Huang; Michael J Avram; Richard Green; Andrew Mazar; Daniel Appella; Zhi Chen; Sui Huang Journal: FASEB J Date: 2017-08-17 Impact factor: 5.191